Literature DB >> 4076227

Medullary-thyroid-carcinoma imaging in an animal model: use of radiolabeled anticalcitonin F(ab')2 and meta-iodobenzylguanidine.

D Guilloteau, J L Baulieu, J C Besnard.   

Abstract

Radiolabeled anti-calcitonin (CT) immunoglobulin fragments (131I-anti-CT F(ab')2) and meta-iodobenzylguanidine (131I-mIBG) were injected into nude mice with a transplanted medullary thyroid carcinoma (MCT). 131I-Anti-CT F(ab')2 proved to be unsuitable for MCT scintigraphic imaging. However, a high mIBG uptake was observed in MCTs, but not in control tumors (mesothelioma). The uptake of mIBG was not modified by the presence of reserpine or pentagastrine. These results are discussed, and it is suggested that mIBG could be an APUD-system marker.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076227     DOI: 10.1007/BF00279068

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  13 in total

1.  Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds.

Authors:  A NISONOFF; F C WISSLER; L N LIPMAN; D L WOERNLEY
Journal:  Arch Biochem Biophys       Date:  1960-08       Impact factor: 4.013

2.  Neurocristopathy, neuroendocrine pathology and the APUD concept.

Authors:  A G Pearse
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975-09-22

3.  Imaging of medullary thyroid cancer with 131I-MIBG.

Authors:  K Endo; K Shiomi; K Kasagi; J Konishi; K Torizuka; K Nakao; H Tanimura
Journal:  Lancet       Date:  1984-07-28       Impact factor: 79.321

4.  Neuroendocrine neoplasms and their cells of origin.

Authors:  A S Tischler; M A Dichter; B Biales; L A Greene
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

5.  A new imaging agent for medullary carcinoma of the thyroid.

Authors:  H Ohta; K Yamamoto; K Endo; T Mori; D Hamanaka; A Shimazu; K Ikekubo; K Makimoto; Y Iida; J Konishi
Journal:  J Nucl Med       Date:  1984-03       Impact factor: 10.057

6.  Platelet uptake of the pheochromocytoma-scanning agent 131I-meta-iodobenzylguanadine.

Authors:  J M Feldman; N Frankel; R E Coleman
Journal:  Metabolism       Date:  1984-05       Impact factor: 8.694

7.  Scintigraphic studies in patients with medullary carcinoma of the thyroid.

Authors:  B Rasmusson
Journal:  Eur J Nucl Med       Date:  1982

8.  Meta-iodobenzylguanidine adrenal medulla localization: autoradiographic and pharmacologic studies.

Authors:  D Guilloteau; J L Baulieu; F Huguet; C Viel; C Chambon; C Valat; F Baulieu; R Itti; L Pourcelot; G Narcisse
Journal:  Eur J Nucl Med       Date:  1984

9.  Uptake and localization of 131I-labeled anti-calcitonin immunoglobulins in rat medullary thyroid carcinoma tissue.

Authors:  K M Gautvik; K Svindahl; A Skretting; B Stenberg; L Myhre; A Ekeland; J V Johannesen
Journal:  Cancer       Date:  1982-09-15       Impact factor: 6.860

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  3 in total

1.  Search for polynuclear pentavalent technetium complex of dimercaptosuccinic acid [Tc(V)-DMS] tumour localization mechanism. I. Medullary thyroid carcinoma animal model.

Authors:  K Horiuchi; I Yomoda; H Ohta; K Endo; A Yokoyama
Journal:  Eur J Nucl Med       Date:  1991

2.  Thyroid uptake of MIBG in Sipple's syndrome.

Authors:  R Perdrisot; V Rohmer; J J Lejeune; J C Bigorgne; P Jallet
Journal:  Eur J Nucl Med       Date:  1988

3.  Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report.

Authors:  D Pach; A Sowa-Staszczak; A Jabrocka-Hybel; A Stefańska; M Tomaszuk; R Mikołajczak; B Janota; M Trofimiuk-Müldner; E Przybylik-Mazurek; A Hubalewska-Dydejczyk
Journal:  Int J Endocrinol       Date:  2013-03-31       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.